Literature DB >> 22952383

Hyperpolarized 3He and 129Xe MR imaging in healthy volunteers and patients with chronic obstructive pulmonary disease.

Miranda Kirby1, Sarah Svenningsen, Amir Owrangi, Andrew Wheatley, Adam Farag, Alexei Ouriadov, Giles E Santyr, Roya Etemad-Rezai, Harvey O Coxson, David G McCormack, Grace Parraga.   

Abstract

PURPOSE: To quantitatively compare hyperpolarized helium 3 (3He) and xenon 129 (129Xe) magnetic resonance (MR) images obtained within 5 minutes in healthy volunteers and patients with chronic obstructive pulmonary disease (COPD) and to evaluate the correlations between 3He and 129Xe MR imaging measurements and those from spirometry and plethysmography.
MATERIALS AND METHODS: This study was approved by an ethics board and compliant with HIPAA. Written informed consent was obtained from all subjects. Eight healthy volunteers and 10 patients with COPD underwent MR imaging, spirometry, and plethysmography. Ventilation defect percentages (VDPs) at 3He and 129Xe imaging were obtained by using semiautomated segmentation. Apparent diffusion coefficients (ADCs) were calculated from 3He (b=1.6 sec/cm2) and 129Xe (b=12 sec/cm2) diffusion-weighted images. VDPs at hyperpolarized 3He and 129Xe imaging were compared with a two-tailed Wilcoxon signed rank test and analysis of variance; Pearson correlation coefficients were used to evaluate the relationships among measurements.
RESULTS: 129Xe VDP was significantly greater than 3He VDP for patients with COPD (P<.0001) but not for healthy volunteers (P=.35), although 3He and 129Xe VDPs showed a significant correlation for all subjects (r=0.91, P<.0001). The forced expiratory volume in 1 second (FEV1) showed a similar and significant correlation with 3He VDP (r=-0.84, P<.0001) and 129Xe VDP (r=-0.89, P<.0001), although the correlation between the FEV1/forced vital capacity (FVC) ratio and 129Xe VDP (r=-0.95, P<.0001) was significantly greater (P=.01) than that for FEV1/FVC and 3He VDP (r=-0.84, P<.0001). A significant correlation was also observed for 3He and 129Xe ADC (r=0.97, P<.0001); 129Xe ADC was significantly correlated with diffusing capacity of lung for carbon monoxide (r=-0.79, P=.03) and computed tomographic emphysema measurements (areas with attenuation values in the 15th percentile: r=-0.91, P=.0003; relative areas with attenuation values of less than -950 HU: r=0.87, P=.001).
CONCLUSION: In patients with COPD, the VDP obtained with hyperpolarized 29Xe MR imaging was significantly greater than that with 3He MR imaging, suggesting incomplete or delayed filling of lung regions that may be related to the different properties of 129Xe gas and physiologic and/or anatomic abnormalities in COPD. © RSNA, 2012

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22952383     DOI: 10.1148/radiol.12120485

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  56 in total

1.  Repeatability of regional pulmonary functional metrics of Hyperpolarized 129 Xe dissolved-phase MRI.

Authors:  Andrew D Hahn; Jeff Kammerman; Michael Evans; Wei Zha; Robert V Cadman; Keith Meyer; Nathan Sandbo; Sean B Fain
Journal:  J Magn Reson Imaging       Date:  2019-04-10       Impact factor: 4.813

2.  Dose and pulse sequence considerations for hyperpolarized (129)Xe ventilation MRI.

Authors:  Mu He; Scott H Robertson; S Sivaram Kaushik; Matthew S Freeman; Rohan S Virgincar; John Davies; Jane Stiles; William M Foster; H Page McAdams; Bastiaan Driehuys
Journal:  Magn Reson Imaging       Date:  2015-04-30       Impact factor: 2.546

3.  Extending semiautomatic ventilation defect analysis for hyperpolarized (129)Xe ventilation MRI.

Authors:  Mu He; S Sivaram Kaushik; Scott H Robertson; Matthew S Freeman; Rohan S Virgincar; H Page McAdams; Bastiaan Driehuys
Journal:  Acad Radiol       Date:  2014-09-26       Impact factor: 3.173

4.  Novel Thoracic MRI Approaches for the Assessment of Pulmonary Physiology and Inflammation.

Authors:  Jonathan P Brooke; Ian P Hall
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  A two-center analysis of hyperpolarized 129Xe lung MRI in stable pediatric cystic fibrosis: Potential as a biomarker for multi-site trials.

Authors:  Marcus J Couch; Robert Thomen; Nikhil Kanhere; Raymond Hu; Felix Ratjen; Jason Woods; Giles Santyr
Journal:  J Cyst Fibros       Date:  2019-03-25       Impact factor: 5.482

6.  Feasibility, tolerability and safety of pediatric hyperpolarized 129Xe magnetic resonance imaging in healthy volunteers and children with cystic fibrosis.

Authors:  Laura L Walkup; Robert P Thomen; Teckla G Akinyi; Erin Watters; Kai Ruppert; John P Clancy; Jason C Woods; Zackary I Cleveland
Journal:  Pediatr Radiol       Date:  2016-08-05

Review 7.  Hyperpolarized and inert gas MRI: the future.

Authors:  Marcus J Couch; Barbara Blasiak; Boguslaw Tomanek; Alexei V Ouriadov; Matthew S Fox; Krista M Dowhos; Mitchell S Albert
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

8.  3D MRI of impaired hyperpolarized 129Xe uptake in a rat model of pulmonary fibrosis.

Authors:  Zackary I Cleveland; Rohan S Virgincar; Yi Qi; Scott H Robertson; Simone Degan; Bastiaan Driehuys
Journal:  NMR Biomed       Date:  2014-05-12       Impact factor: 4.044

9.  Hyperpolarized 129Xenon Magnetic Resonance Imaging to Quantify Regional Ventilation Differences in Mild to Moderate Asthma: A Prospective Comparison Between Semiautomated Ventilation Defect Percentage Calculation and Pulmonary Function Tests.

Authors:  Lukas Ebner; Mu He; Rohan S Virgincar; Timothy Heacock; Suryanarayanan S Kaushik; Matthew S Freemann; H Page McAdams; Monica Kraft; Bastiaan Driehuys
Journal:  Invest Radiol       Date:  2017-02       Impact factor: 6.016

10.  Three-dimensional ultrasound measurements of carotid vessel wall and plaque thickness and their relationship with pulmonary abnormalities in ex-smokers without airflow limitation.

Authors:  Jieyu Cheng; Damien Pike; Tommy W S Chow; Miranda Kirby; Grace Parraga; Bernard Chiu
Journal:  Int J Cardiovasc Imaging       Date:  2016-06-24       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.